zABomba

Walked the Merck booth at #ASCO26. The headline isn't a single new indication. It's that the strategy itself has shifted: checkpoint inhibition is moving into earlier stages of cancer, across seven solid tumors now, including adjuvant Stage IIB/IIC/III melanoma." "That shift is what makes the PRIME-THT study question matter. The earlier you intervene, the more useful it is if you can convert a cold tumor to hot before standard immunotherapy is given. Different mechanism, same direction the field is moving." - Dr. Carman Giacomantonio, CMO @ASCO

Caught up with Dr Carman at #ASCO26 between sessions. He was walking a colleague through the first-in-human melanoma data, what we treated, what came back, where the patients sit at six months of follow-up. Worth sharing in his own words. David Regan, CEO @ASCO #melanoma #asco2026

If you have seen the IGNITE-THT and PRIME-THT studies mentioned and wondered what they actually are, here is the plain version. Both are studies that combine Sona's heat-based approach with immunotherapy, in melanoma patients whose disease has progressed despite standard treatment. Two studies, two patient groups, one question: can adding local heat help the immune system respond where it could not before. They are studies, not products. And what they show could change the direction of cancer care. bit.ly/4uzKzk2 #ASCO2026 #Melanoma #ClinicalTrials @ASCO